Steven Cohen’s Corcept Therapeutics CORT Stock Holding History

Steven Cohen’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56,181	Closed	-$3.39M	–	4091
2026 Q1	$2.26M	Buy	+56,181	New	+$2.1M	﹤0.01%	2226
2023 Q4	–	Sell	-1,690	Closed	-$46K	–	2261
2023 Q3	$46K	Buy	1,690 +1,025	+154%	+$29.7K	﹤0.01%	2151
2023 Q2	$14.8K	Sell	665 -1,884	-74%	-$43.4K	﹤0.01%	1846
2023 Q1	$55.2K	Buy	+2,549	New	+$55.9K	﹤0.01%	1764

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Steven Cohen's CORT Position: Q2 2026 in Review

Steven Cohen sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 56,181 shares — an estimated $3.39M sold.

Steven Cohen first reported a position in CORT in Q1 2023 and held it in 4 quarters. The position peaked at $2.26M in Q1 2026. 420 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Steven Cohen reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 56,181 Corcept Therapeutics shares in Q2 2026, an estimated $3.39M.
Steven Cohen first reported a position in Corcept Therapeutics in Q1 2023 and held it in 4 quarters.
Steven Cohen's Corcept Therapeutics position peaked at $2.26M in Q1 2026.
420 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.